Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Gland Pharma's Free Cash Flow for the
three
months ended in Mar. 2026 was ₹0 Mil. Gland Pharma's Revenue for the
three
months ended in Mar. 2026 was ₹17,428 Mil. Therefore, Gland Pharma's FCF Margin % for the quarter that ended in Mar. 2026 was 0.00%.
The historical rank and industry rank for Gland Pharma's FCF Margin % or its related term are showing as below:
BOM:543245'
s FCF Margin % Range Over the Past 10 Years
Min: 2.48 Med: 8.35 Max: 19.69
Current: 8.35
During the past 9 years, the highest FCF Margin % of Gland Pharma was 19.69%. The lowest was 2.48%. And the median was 8.35%.
BOM:543245's FCF Margin % is ranked better than 66.22% of 962
companies
in the Drug Manufacturers industry
Industry Median: 2.585
vs BOM:543245: 8.35
Gland Pharma FCF Margin % Related Terms
Gland Pharma FCF Margin % Historical Data
* Premium members only.
The historical data trend for Gland Pharma's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Gland Pharma's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Gland Pharma FCF Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Gland Pharma's FCF Margin % distribution charts can be found below:
* The bar in red indicates where Gland Pharma's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Gland Pharma (BOM:543245) has a FCF Margin % of 0.00% as of Mar. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Gland Pharma and its competitors. Over the past decade, Gland Pharma's FCF Margin % has ranged from 2.48 to 19.69. According to the industry distribution chart, Gland Pharma ranks #325 out of 962 companies in the Drug Manufacturers industry, placing it in the top 33.8%.
Is Gland Pharma's FCF Margin % too high?
Gland Pharma's current FCF Margin % is 0.00%. Over the past 10 years, this metric has ranged from a low of 2.48 to a high of 19.69. Based on the distribution chart, Gland Pharma ranks #325 out of 962 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Gland Pharma has a GF Score™ of 84/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Gland Pharma's FCF Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Gland Pharma ranks #325 out of 962 companies for FCF Margin %. This puts Gland Pharma in the upper half of its industry. The industry median FCF Margin % is 2.59. Historically, Gland Pharma's own FCF Margin % has ranged from 2.48 to 19.69 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Drug Manufacturers company?
The median FCF Margin % among Drug Manufacturers companies is 2.59, based on 962 companies in the industry. Companies in the top quartile (top 25%) have a FCF Margin % significantly above this median, while those in the bottom quartile fall well below. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Gland Pharma and its competitors. For the Drug Manufacturers industry, the median FCF Margin % is 2.59 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Gland Pharma's current FCF Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Gland Pharma stock overvalued right now?
Based on GuruFocus' analysis, Gland Pharma (BOM:543245) is currently considered Modestly Overvalued. The stock's GF Value™ is ₹2,147.94, compared to a current price of ₹2,440.25 — trading 13.6% above its estimated fair value. The current FCF Margin % is 0.00%. Gland Pharma's overall GF Score™ is 84/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Gland Pharma (BOM:543245), the current FCF Margin % is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Gland Pharma (BOM:543245) Overvalued in 2026?
Based on GuruFocus' analysis, Gland Pharma stock appears to be overvalued.
The current stock price of ₹2,440.25 is trading 13.6% above its estimated GF Value™ of ₹2,147.94.
GuruFocus considers Gland Pharma to be Modestly Overvalued.
Key valuation signals for BOM:543245:
FCF Margin %: 0.00%
GF Value™: ₹2,147.94 vs. price of ₹2,440.25 (13.6% above fair value)
No single metric tells the full story. See the BOM:543245 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Gland Pharma Ltd is engaged in the development, manufacturing, and marketing of complex injectables. The company's key molecules include Heparin Sodium Injection, Enoxaparin Sodium Injection, Rocuronium Bromide Injection, and Daptomycin Injection, among others. The group is also involved in a vast range of therapeutic categories, including Anti-Infectives, Anesthetics, Anti-Coagulants and their Antidotes, Anti-Malarials, Cardiology, and more, to Hormones and related Drugs, Fertility Supplements, and GnRH Agonists and Antagonists. Geographically, it derives a majority of revenue from the USA, and the rest from Europe, India, Canada, Australia, and other regions.
84GF Score
Get the complete analysis for BOM:543245
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:543245 has been successfully added to your 
